Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care (SAMICU)

University Hospital, Strasbourg, France

Status: Enrolling

Conditions: Cirrhosis, Liver; Hepatic Insufficiency

Study type: Observational

Funder types: Other

Identifiers

NCT07343037

9818

Details and patient eligibility

About

Patients with hepatocellular insufficiency and/or cirrhosis are at risk of developing invasive fungal infections, particularly in critical care settings.

In international recommendations, voriconazole is positioned as the first-line treatment for invasive aspergillosis. However, this molecule-and the azole class of antifungals-is associated with frequent hepatic toxicity. Available since 2018, isavuconazole appears to be better tolerated in patients without pre-existing liver dysfunction.

The aim of this study is to retrospectively evaluate the validity of the hscore in intensive care and resuscitation patients.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patient (≥18 years old)

• Patient admitted to the intensive care unit at Hautepierre Hospital, Strasbourg University Hospital, between January 1, 2014, and December 31, 2024

• At least 3 biological signs of HLH:

  • ferritin > 2000 ng/mL
  • triglycerides > 1.5 g/L
  • at least one cytopenia (leukocytes ≤ 5000 G/L, platelets ≤ 110 G/L, hemoglobin ≤ 9.2 g/dL).

Exclusion criteria

Refusal to participate in the study